AstraZeneca Pharma India Ltd announced that it received a draft income tax order regarding assessment year 2022-23 on March 19, 2025, proposing an adjustment of approximately Rs. 11.96 crores related to legacy transfer pricing issues, which will be challenged before a Dispute Resolution Panel.